New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC

KARD

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

11.54 0.98 −7.83%

After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.

Market cap
$1.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−187.2%
Net debt / EBITDA
1.7×
Payout ratio
—

What it owns vs. what it owes End of fiscal 2025, Dec 31, 2025

Liabilities are $250.3M more than assets: shareholders’ equity is negative. What is a balance sheet?

Dec 31, 2025 · total $390.9M

Owns

$45.6MLong-term assets
$9.9MOther short-term assets
$335.5MCash & short-term investments

Funded by

$641.3MOther liabilities

Debt is 0.00% of the total; liabilities are $250.3M more than assets.

Dec '24 Dec '25
Total current assets
50.32 345.35
Total non-current assets
13.21 45.59
Total Assets
63.53 390.94
Total current liabilities
8.29 37.54
Total non-current liabilities
138.44 603.74
Total liabilities
146.72 641.28
Common Equity (Total)
(83.19) (250.33)
Shareholders Equity (Total)
(83.19) (250.33)

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026